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staging Carcinoma of the Prostate
Joseph C. Cerny, MD*

or patients with carcinoma of the prostate, staging is cmcial
in determining the severity of the disease, its prognosis, and
how therapy will be guided. The staging categories, staging
methods and their applications, and the impact of staging on
therapeutic results and patient management are discussed
herein.

F

Staging Systems
The most widely used staging nomenclature is the modified
Whitmore-Jewett system. Most urologists are familiar with this
system as it is commonly used in clinical situations and has been
widely discussed in the literature. Stage A represents the incidental finding of carcinoma, usually discovered after transurethral prostatectomy for obstmction. In stage A-l less than 5%
of the resected tissue is neoplastic and well differentiated,
whereas in stage A-2 greater than 5% of thetissueis neoplastic
and/or poorly differentiated. In stage B the lesion is palpable
and confined to the prostate gland. In stage B-l the nodule is
confined to less than one lobe and is surrounded by normal prostatetissue,whereas in stage B-2 the palpable nodule is more extensive, usually involving one ormore lobes, though still within
the confines of the prostate gland. In stage C the carcinoma extends beyond the prostate, but without distant metastases. Minimal extracapsular extension is seen in stage C-1, and stage C-2
consists of bulky tumor with bladder outiet and/or ureteral
obstmction. Distant metastases characterize stage D. In stage
D-1 pelvic lymph node metastases are found by surgery or by
needle biopsy. In stage D-2 distant metastatic disease is evident,
usually in the bones, whereas stage D-3 indicates a relapse following endocrine therapy.
The tumor, node, metastasis (TNM) staging system, which is
preferred in many parts of the world including Europe, has the advantage of describing the status of the local disease as well as the
extent of the nodal involvement and distant disease. While most
urologists and oncologists prefer the modified Whitmore-Jewett
system to the TNM system, some combination of these two systems will ultimately provide a universal staging system (1).

Serum Studies
Following the histologic diagnosis of prostatic adenocarcinoma, semm studies are necessary for accurate staging of the
disease. These include prostatic acid phosphatase (PAP), alkaline phosphatase, and prostate specific antigen (PSA).
While semm studies are essential to the staging process, idiosyncracies of each of these biochemical parameters have limited
specificity in describing the precise status of the neoplasm. Interpretation of acid phosphatase levels in individual patients is
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difficult because results may be normal both in patients with
cancer confined to the prostate gland and in up to 30% of patients
with metastatic disease. Conversely, some patients with benign
prostatic hypertrophy (BPH), as well as those with nonprostatic
disease such as osteitis deformans (Paget disease), multiple myeloma, or blood dyscrasias may have elevated semm acid phosphatase. Furthermore, patients who have had recent urethral instrumentation or palpation of a benign prostate gland may
exhibit transient (24 to 48 hr) elevation of PAP. Compared to enzymatic assays for measuring PAP, radioimmunoassays and
counterimmunoelectrophoresis are more sensitive, but the frequent occurrence of false-positive results makes these tests unacceptable for screening purposes.
Elevation of alkaline phosphatase in patients with carcinoma
ofthe prostate is associated with metabolic bone repair in an area
of osseous metastasis as well as with liver disease. The semm
alkaline phosphatase level is particularly useful in documenting
response to endocrine therapy in patients with skeletal metastases (2).
PSA has recently been evaluated as a marker in BPH and in
localized and disseminated carcinoma of the prostate. Thus, in
patients with BPH, PSA levels greater than 4 |xg/L (normal = 0
to 4 |i.g/L) were noted in 20% of patients and levels greater than
10 |jLg/L were noted in another 3% to 5% of patients. In localized
carcinoma of the prostate, PSA levels greater than 4 ji-g/L were
noted in 60% of patients and levels greater than 10 p-g/L were
noted in 30% to 50% of patients. In active stage D-2 disease,
PSA levels greater than 4 p-g/L occurred in 98% of patients.
Comparison of PAP levels in control patients and in those
with BPH and carcinoma of the prostate stages A through D
demonstrates that while not much difference exists between
BPH and stages A and B prostate carcinoma, PAP levels progressively increase with advancing stages of carcinoma of the
prostate. Thus, as noted by Ercole et al (3), PAP is elevated in
10% of patients with stage A, 24% with stage B, 53% with stage
C, and 92% with stage D disease. Since significant elevations of
PAP are found in patients with BPH, PAP is not recommended
for screening but is a useful marker in monitoring patients with a
known diagnosis of carcinoma of the prostate.
Comparison of PAP and PSA in carcinoma of the prostate is of
interest. In a recent study, PAP and PSA were studied in 136 con-
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secutive patients. The disease was localized in 43 patients and
had metastasized in 94 patients. The overall sensitivity of PSA
was 89% whereas PAP was 62%. In localized disease only, sensitivity of PSA was 79% and PAP 41%, while in metastatic disease PSA was 93% sensitive, PAP 72%, and alkaline phosphatase 63%. In another study correlating semm PAP levels and
final pathologic stage as determined on the radical prostatectomy specimen, patients with capsular penetration had the highest percentage of elevated levels of PAP, whereas those with
seminal vesicle involvement had intermediate elevation, and
patients with node involvement had the lowest correlation (4).

sion (6). These areas can be selectively sampled in patients in
whom stage C disease is suspected. Since most patients with
stage C disease are candidates for radiation therapy or hormonal
therapy and not radical prostatectomy, an ultrasound-guided biopsy of this area is imperative. Similarly, the pelvic CT scan is
useful in showing the prostatic capsule and the possibility of dismpdon. MRI has also been useful in staging involvement ofthe
bladder neck and seminal vesicles (7). At Henry Ford Hospital
we prefer to use the ultrasound-guided perineal needle biopsy,
although transrectal ultrasound-guided biopsies are also performed. A study of 27 patients with biopsy-proven prostatic carcinoma compared the sensitivity of MRI and ultrasound to each
other and to CT in staging the disease. Sonography was superior
Understaging
Understaging occurs in a significant percentage of patients to MRI for detection of intraglandular carcinoma and capsular
with prostate carcinoma, with the clinical stage typically lower dismption, whereas MRI was superior to both sonography and
than the true pathologic stage. In patients presumed to have CT for evaluating seminal vesicle invasion and was slightly betstage A - l , B-l, and B-2 carcinoma, the frequency of both micro- ter than CT for detecting lymphadenopathy (8).
scopic and macroscopic local tumor invasion in radical prostatectomy specimens was from 15% to 30%. In clinical stages
Conclusions
A-2, B-l, and B-2, significant percentages of capsular invasion,
Errors
are
inherent
in
all staging procedures. Once staging
seminal vesicle invasion, and lymph node metastasis were
found. According to Epstein et al (5), in padents with presumed data are obtained and assembled, the urologist must discuss with
A-l disease, based on transurethral prostatectomy, subsequent the patient and his family the pros and cons of extemal radiation
radical prostatectomy revealed an 86% incidence of significant therapy and radical prostatectomy for the treatment of stage A-1,
residual disease and in many cases large volume residual dis- A-2, B-l, and B-2 disease. Both modalities have been considease. Interestingly, no correlation existed between the amount of ered equal in the treatment of prostate carcinoma. However,
neoplasm found on the transurethral specimen, or its grade, and based on results obtained with the recently introduced nervesparing technique, 1 prefer that young and otherwise healthy pasubsequent volume of tumor in the radical specimen.
tients with localized, early stage prostatic carcinoma be treated
by radical prostatectomy rather than with external radiation
Radiologic Studies
therapy.
Radiologic studies used in the staging of prostate carcinoma
include chest x-ray, bone scans and skeletal x-rays, intravenous
pyelograms, lymphangiography, prostatic ultrasound, comReferences
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